BriaCell Therapeutics Corp.
BCTXAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 27, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 22, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 24, 2024 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 28, 2026 | $-1.24 | — | — | — |
| Jun 9, 2026 | $-0.99 | — | — | — |
| Mar 10, 2026 | $-2.58 | $-4.84 | — | — |
| Dec 11, 2025 | $-4.35 | $-3.28 | — | $2.1M |
| Oct 27, 2025 | $-10.49 | $-12.11 | — | — |
| Jun 16, 2025 | $-1.64 | $-17.60 | — | — |
| Mar 12, 2025 | $-23.30 | $-19.40 | — | — |
| Dec 16, 2024 | $-32.98 | $-0.30 | — | — |
News
Shares of Briacell Therap (NASDAQ: BCTX - Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $3.79 and traded as high as $4.08. Briacell Therap shares last traded at $3.95, with a volume of 158,152 shares trading hands. Analyst Ratings Changes Separately, Weiss Ratings
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced preclinical findings from four posters at the Society for Immunotherapy of Cancer (SITC) 41th Anniversary Annual Meeting, taking place Nove…
LOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, announced today that it has awarded BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, for “Immunotherapy Solution …
Four presentations highlight BriaCell's Bria-OTS+™ cellular immunotherapy platform and BriaPro's CD80-based immunotherapy programs In vitro Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing across breast, prostate and lung cancer models BriaPro data describes BP-80 tolerability in nonhuman primates and engineered CD80 constructs with enhanced PD-L1 binding PHILADELPHIA and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq…
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with metastatic breast cancer (“MBC”) treated with immune based therapies including the BriaCell regimen at the Europea…
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentati…
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immun…
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell's ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NC…
Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturing Program builds on BriaCell's experience in metastatic breast cancer and prostate cancer, further expanding its therapeutic vaccine platform Melanoma remains a significant unmet medical need, with approximately 112,000 new cases and 8,510 deaths expected in …